euro adhoc: Intercell AG / Joint Ventures/Cooperation/Collaboration / Intercell update on technology partnerships: Intercell outlicenses Group B Streptococcus vaccine

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

19.12.2008

» Group B Streptococcus vaccine program licensed to Novartis -
Intellectual property cross license agreement will allow Novartis
to focus on vaccines and Intercell on therapeutic antibodies in
this indication » Extension of collaboration with Sanofi Pasteur on
undisclosed bacterial vaccine towards product development »
Pre-clinical evaluation of IC31® with Wyeth in multiple infectious
vaccine indications progressing well » Revenues and revenue
recognition from technology partnerships in the fourth quarter 2008
expected to clearly exceed EUR 10 m

Vienna (Austria), December 19, 2008 - Intercell today announced that
the Company has transferred on an exclusive basis its pre-clinical
Group B Streptococcus (GBS) vaccine program to Novartis. At the same
time Intercell has kept and received co-exclusive rights for the
development of therapeutic antibodies against Group B Streptococcus
and has in-licensed additional rights on GBS antibodies from
Novartis. The GBS vaccine program was part of the vaccine portfolio
for which Intercell had granted license options to Novartis under a
strategic partnership closed in 2007. This step will trigger a
recognition of revenue from the upfront option fee received under
this strategic partnership.

Furthermore, the collaboration with Sanofi Pasteur, to discover and
develop a vaccine against an un-disclosed bacterial pathogen, has
been extended in order to define a vaccine candidate for development.

The collaboration with Wyeth to use Intercell's proprietary adjuvant
IC31® in various bacterial vaccine targets, which are in pre-clinical
development, is progressing well. The collaboration runs under a
non-exclusive agreement signed in 2006.

"We are very pleased that all our technology partnerships are
progressing very well," states Gerd Zettlmeissl, Chief Executive
Officer of Intercell. "This demonstrates that our Antigen
Identification Program, our adjuvant IC31® and Intercell's new patch
technology are valuable assets of our Company. Given the richness of
our pipeline we will even extend our portfolio of product development
alliances where we expect new partnerships in the near future," adds
Zettlmeissl.

Intercell expects revenues and revenue recognition from existing
technology partnerships to clearly exceed EUR 10m in the fourth
quarter of 2008.

About Group B Streptococcus

Intercell has identified and validated numerous antigens from Group B
Streptococcus (GBS). The most promising antigens will be refined and
used to prevent diseases in the most susceptible neonates (not yet
born and newborn with a weight of less than 1,000 g). In addition,
antibodies will also be given to neonates who already developed
diseases caused by GBS. The vaccine is currently in pre-clinical
development.

GBS causes infections of diverse kind in neonates (not yet born),
newborns, pregnant women and elderly. An infection can result in lung
inflammation (pneumonia), life-threatening systemic inflammatory
response syndrome (sepsis) and brain and cerebrospinal fever
(meningitis). Newborns are at especially high risk for infections and
acquire the infection from their infected mothers, even though the
mothers may be without symptoms.

About IC31®

Vaccines, based on antigens alone, are not always sufficient to
provide full protection. Adjuvants are needed to educate the immune
system to recognize and eliminate the pathogens efficiently.

IC31® is an adjuvant that induces T-cell and B-cell responses by
using a unique synthetic formulation which combines the
immunostimulating properties of an anti-microbial peptide, KLK, and
an immunostimulatory oligodeoxynucleotide, ODN1a. The two component
solution can be simply mixed with antigens; no conjugation is
required.

Intercell currently uses IC31® in collaborations with a number of
global vaccine companies and biotech companies. These collaborations
include amongst others the development of a tuberculosis vaccine in
Phase I clinical trials, which has been partnered with the Danish
Statens Serum Institut and Sanofi Pasteur.

About Intercell's Antigen Identification Program (AIP®)

The design and development of novel subunit vaccines is highly
dependent on the identification and characterization of the proper
antigens. Through AIP® we successfully have identified and refined a
large number of antigens of numerous bacterial pathogens. The
selected antibodies are derived from infected or healthy exposed
individuals and therefore directly mirror the presence, accessibility
and antigenicity of relevant proteins from the particular
microorganism in its human host. The most promising candidates are
validated. AIP® has successfully been applied to identify a large
number of novel antigens from numerous pathogenic organisms including
S. aureus, S. epidermidis, S. pneumoniae, S. agalactiae, S. pyogenes,
E. faecalis, K. pneumoniae, Borrelia spp., ETEC, Shigella, C. jejuni,
non-typeable H. influenzae and M. catarrhalis. It has resulted in
promising in-house product candidates and generated strategic
partnerships.

About Intercell's vaccine patch technology

Intercell's Vaccine Patch is a new and needle free delivery
technology which can be used to:

» Enhance the effect of injected vaccines: Vaccine Enhancement
Patch (VE Patch) » Develop new vaccines which require transcutaneous
administration because the antigen can not be delivered safely or
efficiently through other routes of administration: Vaccine Patch

The patch technology opens up a new way of vaccine delivery that is
easier to administer, faster to deliver and can result in lower or
fewer doses. The patch can boost cellular immunity to a diverse range
of antigens and stimulates both B-cell and T-cell responses. It
contains the heat labile enterotoxin from E. coli (LT), one of the
most potent stimulators of the immune system. When the patch is
applied on the skin, immune stimulants are delivered at the surface
of the skin to Langerhans cells, a major component of the immune
systems. The Langerhans cells, activated by the presence of these
immune stimulants, take up the vaccine antigen and migrate to the
regional draining lymph nodes. There, presentation to the immune
system occurs, eliciting a robust immune response.

Compared with standard immunization via needles, the patch technology
has significant benefits. It is easily administered, the antigen and
adjuvant are directly delivered to the immune system through the
natural defense pathway, which makes vaccination efficient and
results in less side effects. The patch has shown excellent local
tolerability, it is stable at room temperature and strong immune
stimulants can be used since there is no systemic exposure.

At present, the Vaccine Patch is used in-house for the development of
a novel Travelers' Diarrhea vaccine patch about to enter Phase III
trials and the Vaccine Enhancement Patch in the development of a
pandemic Influenza vaccine patch. In addition, the technology is used
in collaboration with Merck & Co., which uses it to conduct
proof-of-principle pre-clinical studies. Intercell is seeking further
collaborations with leading industry players interested in developing
vaccines where fewer doses are desired, product life-cycle management
is needed or use in immune-compromised patients is required.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market